After a slow week, the IPO train is back up and running as 3 more biotechs hop aboard

After the IPO market cooled off last week — not just in pharma but the entire market, which saw only one public debut according to Renaissance Capital — three more biotechs filed their S-1 paperwork Friday.

The new entrants are Prometheus Biosciences, Longboard Pharmaceuticals and Gain Therapeutics. Prometheus is penciling in the highest raise of the group, estimating a $125 million influx of cash. Longboard is seeking $86 million, while Gain is looking to raise $40 million.